Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10365 in advanced solid tumors
NCT05207787Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2021
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of resencatinib in solid tumor, non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC) and 1 more, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose or Maximum Administrated Dose at 28 days and Objective Response Rate at 24 months. Started Nov 2021; status: recruiting.
02
Drugs
resencatinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)medullary thyroid carcinoma (MTC)thyroid cancer
Beyond the preview
Go deeper on NCT05207787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207787.